ES2742224T3 - Anticuerpos biespecíficos anti-WT1/HLA - Google Patents
Anticuerpos biespecíficos anti-WT1/HLA Download PDFInfo
- Publication number
- ES2742224T3 ES2742224T3 ES14803300T ES14803300T ES2742224T3 ES 2742224 T3 ES2742224 T3 ES 2742224T3 ES 14803300 T ES14803300 T ES 14803300T ES 14803300 T ES14803300 T ES 14803300T ES 2742224 T3 ES2742224 T3 ES 2742224T3
- Authority
- ES
- Spain
- Prior art keywords
- seq
- amino acid
- set forth
- acid sequence
- sequence set
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CCCCCCC*(*)(CCS*C(*)*)OOOC(CC1)C[C@@]1C1(C*)*C1 Chemical compound CCCCCCC*(*)(CCS*C(*)*)OOOC(CC1)C[C@@]1C1(C*)*C1 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361901310P | 2013-11-07 | 2013-11-07 | |
| US201462037875P | 2014-08-15 | 2014-08-15 | |
| PCT/US2014/064621 WO2015070061A1 (en) | 2013-11-07 | 2014-11-07 | Anti-wt1/hla bi-specific antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2742224T3 true ES2742224T3 (es) | 2020-02-13 |
Family
ID=51987482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14803300T Active ES2742224T3 (es) | 2013-11-07 | 2014-11-07 | Anticuerpos biespecíficos anti-WT1/HLA |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP3066130B1 (enExample) |
| JP (1) | JP6553069B2 (enExample) |
| CN (1) | CN106414500B (enExample) |
| ES (1) | ES2742224T3 (enExample) |
| WO (1) | WO2015070061A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| HK1258444A1 (zh) | 2015-10-09 | 2019-11-15 | Immatics Biotechnologies Gmbh | 抗wt1/hla特异性抗体 |
| WO2017070608A1 (en) | 2015-10-23 | 2017-04-27 | Eureka Therapeutics, Inc. | Antibody/t-cell receptor chimeric constructs and uses thereof |
| WO2017124001A2 (en) * | 2016-01-14 | 2017-07-20 | Memorial Sloan-Kettering Cancer Center | T cell receptor-like antibodies specific for foxp3-derived peptides |
| EP4491234A3 (en) | 2017-02-08 | 2025-04-09 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| BR112019017197A2 (pt) | 2017-02-20 | 2020-04-14 | Dragonfly Therapeutics, Inc. | proteínas que se ligam a her2, nkg2d e cd16 |
| CN110741016A (zh) | 2017-04-26 | 2020-01-31 | 优瑞科生物技术公司 | 嵌合抗体/t-细胞受体构筑体及其用途 |
| US12178830B2 (en) | 2017-06-30 | 2024-12-31 | Memorial Sloan Kettering Cancer Center | Compositions and methods for adoptive cell therapy for cancer |
| JP7072792B2 (ja) * | 2017-12-11 | 2022-05-23 | 国立大学法人神戸大学 | 二重特異性抗体 |
| EP3728317A2 (en) | 2017-12-21 | 2020-10-28 | F. Hoffmann-La Roche AG | Antibodies binding to hla-a2/wt1 |
| PE20220278A1 (es) | 2018-02-08 | 2022-02-25 | Dragonfly Therapeutics Inc | Dominios variables de anticuerpos que se dirigen al receptor nkg2d |
| AU2019218125B2 (en) | 2018-02-08 | 2025-03-13 | Dragonfly Therapeutics, Inc. | Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells |
| WO2019161133A1 (en) | 2018-02-15 | 2019-08-22 | Memorial Sloan Kettering Cancer Center | Foxp3 targeting agent compositions and methods of use for adoptive cell therapy |
| TW201942134A (zh) | 2018-02-20 | 2019-11-01 | 美商蜻蜓醫療公司 | 結合cd33、nkg2d及cd16之多特異性結合蛋白及使用方法 |
| CA3100775A1 (en) * | 2018-05-18 | 2019-11-21 | Children's National Medical Center | Improved targeted t-cell therapy |
| KR20250112921A (ko) | 2018-08-08 | 2025-07-24 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| EA202190468A1 (ru) | 2018-08-08 | 2021-07-06 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения |
| US20240383999A1 (en) * | 2020-04-02 | 2024-11-21 | The Board Of Regents Of The University Of Texas System | Cd5l-binding antibodies and uses for the same |
| EP4146271A4 (en) | 2020-05-06 | 2024-09-04 | Dragonfly Therapeutics, Inc. | PROTEINS THAT BIND NKG2D, CD16 AND CLEC12A |
| EP4216998A1 (en) * | 2020-09-24 | 2023-08-02 | F. Hoffmann-La Roche AG | Prevention or mitigation of t-cell bispecific antibody-related adverse effects |
| CN116635064A (zh) | 2020-12-18 | 2023-08-22 | 世纪治疗股份有限公司 | 具有适应性受体特异性的嵌合抗原受体系统 |
| US12377144B2 (en) | 2021-03-03 | 2025-08-05 | Dragonfly Therapeutics, Inc. | Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen |
| KR20240158351A (ko) * | 2022-03-22 | 2024-11-04 | 모르포시스 아게 | Cd3에 특이적인 탈면역화 항체 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5885573A (en) * | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| JP4948174B2 (ja) * | 2003-10-16 | 2012-06-06 | マイクロメット アクツィエン ゲゼルシャフト | 多重特異的脱免疫ｃｄ３−結合物質 |
| RU2008129827A (ru) * | 2005-12-21 | 2010-01-27 | МЕДИММЬЮН, ЭлЭлСи (US) | МОЛЕКУЛЫ EphA2-BiTE И ИХ ПРИМЕНЕНИЕ |
| PH12013502043A1 (en) * | 2011-04-01 | 2013-12-16 | Memorial Sloan Kettering Cancer Center | T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2 |
-
2014
- 2014-11-07 JP JP2016553248A patent/JP6553069B2/ja not_active Expired - Fee Related
- 2014-11-07 ES ES14803300T patent/ES2742224T3/es active Active
- 2014-11-07 WO PCT/US2014/064621 patent/WO2015070061A1/en not_active Ceased
- 2014-11-07 CN CN201480061156.9A patent/CN106414500B/zh not_active Expired - Fee Related
- 2014-11-07 EP EP14803300.4A patent/EP3066130B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3066130B1 (en) | 2019-05-15 |
| EP3066130A1 (en) | 2016-09-14 |
| CN106414500A (zh) | 2017-02-15 |
| JP6553069B2 (ja) | 2019-07-31 |
| CN106414500B (zh) | 2020-04-10 |
| WO2015070061A1 (en) | 2015-05-14 |
| JP2017500057A (ja) | 2017-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2742224T3 (es) | Anticuerpos biespecíficos anti-WT1/HLA | |
| ES2809455T3 (es) | Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20 | |
| ES2914177T3 (es) | Anticuerpos anti-OX40 humanizados y usos de los mismos | |
| US10239952B2 (en) | Anti-WT1/HLA bi-specific antibody | |
| ES2955074T3 (es) | Proteínas que se unen a HER2, NKG2D Y CD16 | |
| ES2935120T3 (es) | Anticuerpos anti-PSMA, moléculas de unión a antígeno biespecíficas que se unen a PSMA y a CD3, y sus usos | |
| ES2845924T3 (es) | Interruptores de células T con receptores de antígenos quiméricos peptídicos y usos de los mismos | |
| US11091546B2 (en) | Optimized PNE-based chimeric receptor T cell switches and uses thereof | |
| ES2948807T3 (es) | Anticuerpos anti CD3, moléculas de unión a antígeno biespecíficas que se unen a CD3 y a CD20 y usos de los mismos | |
| ES2978993T3 (es) | Terapia de enfermedades mediante la inducción de la respuesta inmunitaria a las células que expresan Trop-2 | |
| US12491244B2 (en) | Pharmaceutical combinations for treating tumor comprising anti-CD19 antibody and natural killer cell | |
| ES2784131T3 (es) | Polipéptidos de unión beta del receptor PDGF | |
| KR20210013160A (ko) | 다중-특이적 결합 단백질 및 그에 대한 개선 | |
| ES2717308T3 (es) | Células madre pluri- o multi-potentes genéticamente modificadas y sus usos | |
| CN109843325A (zh) | Cd3结合抗体 | |
| US10934331B2 (en) | Methods for enhancing immune responsiveness in an individual toward a target cancer cell population comprising apoptotic cells | |
| ES2800674T3 (es) | Polipéptidos biespecíficos de unión a antígeno | |
| US20250388687A1 (en) | Epo receptor agonists and antagonists | |
| AU2014346648A1 (en) | Fc-enhanced anti-WT1/HLA antibody | |
| KR20220150274A (ko) | Il-7 단백질과 이중특이적 항체의 조합물을 사용한 종양의 치료 방법 | |
| EP4545562A1 (en) | Fusion protein comprising anti-cd73 antibody and il-2, and use thereof | |
| HK1227903A1 (en) | Anti-wt1/hla bi-specific antibody | |
| HK1227903B (en) | Anti-wt1/hla bi-specific antibody | |
| Akkapeddi | Antibody based therapy for T-cell acute lymphoblastic leukemia: targeting IL-7 receptor | |
| CA3191224A1 (en) | Multispecific binding compounds that bind to pd-l1 |